|View printer-friendly version|
Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
Presentations will begin at
Key R&D Day Highlights
Inarigivir Clinical Program – the Broadest in Chronic Hepatitis B
“Utilizing our knowledge of the safety, efficacy and mechanism of action of inarigivir from the ACHIEVE trial in combination with the recently-issued FDA Draft Guidance on HBV, we believe that we have a pathway for development of inarigivir that could lead to global Phase 3 trials as early as 2020, in both treatment-naïve and NUC-suppressed patients,” said Dr.
SB 11285 & the Second-Generation STING Agonist Program
“We are excited about our second-generation STING agonist compounds that are differentiated by novel chemistry that allow for enhanced cellular uptake, the capability to be administered systemically as well as intratumorally, and the potential to be developed as antibody drug conjugates (ADCs) and as nanoparticle formulations,” stated Dr. Radhakrishnan Iyer, co-founder and chief scientific officer of Spring Bank.
New R&D Programs Utilizing Small Molecule Nucleic Acid Platform & Chiral Technology Expertise
Participating Key Opinion Leaders
Statements in this press release about Spring Bank’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the company’s general plans and timing for clinical development of inarigivir and SB 11285, the company’s planned clinical trial designs for CATALYST 1 and CATALYST 2, and the anticipated timeline to begin a phase 3 trial for SB 9225.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.